TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Approvals & Labels

GSK score MHLW (Japan) approval for myelofibrosis treatment
Small molecule, primary myelofibrosis - Read more

Valneva lands Health Canada approval for chikungunya virus vaccine
Vaccine, viral infection, chikungunya virus - Read more

Daiichi-Sankyo’s MHLW approval for T-cell lymphoma therapy
Small molecule, T-cell lymphoma, cancer - Read more

Checkpoint Therapeutics checks off BLA resubmission strategy with FDA
Monoclonal antibody, squamous cell carcinoma - Read more

THE GOOD
Business Development

Pfizer lands UK RSV vaccine contract, beating out local GSK
Vaccine, respiratory syncytial virus - Read more

Amylyx Pharmaceuticals eiger-ly buys GLP-1 asset from bankrupt Eiger Pharmaceuticals
$35.1M asset purchase
GLP-1, post-bariatric hypoglycemia, congenital hyperinsulinism - Read more

CombiGene enters into licensing agreement with Spark Therapeutics
No upfront or milestone payments, Spark gets “low single digit” percentage royalties on future net sales
Gene therapy, epilepsy - Read more

THE GOOD
Clinical Trials

Alnylam’s slam dunk Ph3 heart disease data
siRNA, small interfering RNA, transthyretin amyloidosis cardiomyopathy - Read more

Adicet Bio IND approved for carcinoma cell therapy, Ph1 slated for H2 2024
Allogeneic "off-the-shelf" gamma delta CAR T cell therapy, renal cell carcinoma - Read more

Altimmune is coming for big pharma with “best in class” Ph2 obesity data
GLP-1/glucagon dual receptor agonist, obesity, weight loss - Read more

Novo Nordisk shares detailed hemophilia A Ph3 clinical data
Bispecific antibody, hemophilia A - Read more

Takeda’s blood disease antibody may be “deprioritized”, but it still delivered the Ph2 goods
Monoclonal antibody, primary immune thrombocytopenia - Read more

Jiangsu Hengrui Pharmaceuticals obesity asset (out-licensed to Hercules CM NewCo) delivers positive Ph2 data
GLP-1/GIP, obesity, weight loss - Read more*
*you need to search “HRS9531” to find the right abstract

THE GOOD
Company Launches

SAVA uncloaks with $8M
Medical device, real-time health monitoring, interstitial fluid - Read more

THE GOOD
Fundraises

Entrada Therapeutics $100M direct offering
Endosomes, RNA, antibody, neuromuscular - Read more

EpilepsyGTx $10M Seed
Gene therapy, focal refractory epilepsy - Read more

Vico Therapeutics €11.5M ($12.4M) Additional Series B
Antisense oligonucleotide, spinocerebellar ataxia, Huntington’s - Read more

BillionToOne $130M Series D
Molecular counting, liquid biopsy, cancer - Read more

Ocon Therapeutics $10M fundraise
Medical device, stent, 3D drug delivery - Read more

THE GOOD
Investments

Novo Nordisk colossal $4.1B facility plans in North Carolina
GLP-1, obesity, diabetes, manufacturing - Read more

THE GOOD
IPOs

Alumis quantifies IPO ambitions, aiming for a $300M+ raise
Small molecule, plaque psoriasis, uveitis, systemic lupus erythematosus - Read more

After much pain, GRAIL and Illumina officially split ways, GRAIL to list on Nasdaq
Diagnostics, cancer screening - Read more

Ascentage Pharma makes initial IPO moves
Small molecule, cancers, hepatitis B - Read more

LB Pharmaceuticals preps for alleged IPO filing
Small molecule, schizophrenia - Read more [Paywall]

THE GOOD
Market Reports

Big Brain moves; the top 10 “smartest” biopharma M&A deals - Read more

THE GOOD
Mergers & Acquisitions

ANI Pharmaceuticals buys Alimera Sciences
Small molecule diabetic macular edema, posterior uveitis - Read more

THE GOOD
Partnerships

OSE Immunotherapeutics commercial and revenue-sharing partnerships with Memorial Sloan Kettering Cancer Center
CAR-T cell therapy, hematological tumors, cancer - Read more

THE GOOD
Research

Fractyl Health wants obesity treatment to meet gene therapy
Pancreatic gene therapy, AAV, obesity - Read more

THE BAD
Clinical Trials

Merck KGaA cuts head and neck cancer Ph3 short, drops asset
Small molecule, squamous cell carcinoma - Read more

G1 Therapeutics Ph3 breast cancer trial returns dud results
Small molecule, breast cancer - Read more

THE BAD
Company Shutdowns

eFFECTOR Therapeutics winds down
Small molecule, solid tumors, cancer - Read more

THE BAD
Earnings & Finances

Beyond Air reports less than up-lifting Q4 financials
Nitric oxide, respiratory illness, neurological disorders, solid tumors - Read more 

THE BAD
Layoffs

Bridge Biotherapeutics shutters Boston drug-discovery office
Small molecule, gene therapy, cancer, fibrotic diseases - Read more [Paywall]

THE UGLY
Cybersecurity

Data stolen from NHS-linked Synnovis allegedly published online
Pathology laboratory, blood tests - Read more

THE UGLY
Patient Access

Lack of financial incentives mean some rare disease gene therapies left by the biotech wayside - Read more

THE UGLY
Regulatory

FDA scrutinized for seemingly inconsistent inspections across India and China - Read more

THE UGLY
Public Health

Infant deaths increased in Texas after early pregnancy abortion ban; study
Abortion, infant health, pregnancy - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 400+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.